Evidence map›Paper›PMID 34366353›Full record

ArticleJournal of Alzheimer's disease : JAD2021

Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer's Disease but Are Not Correlated with Cognitive Decline.

Amber Nous, Mandy Melissa Jane Wittens, Yannick Vermeiren, Peter Paul De Deyn, Christine Van Broeckhoven, Guy Nagels, Ilse Smolders, Sebastiaan Engelborghs

Open access · bronzeAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Amber NousDepartment of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Mandy Melissa Jane WittensDepartment of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Yannick VermeirenDepartment of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Peter Paul De DeynDepartment of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Christine Van BroeckhovenDepartment of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Guy NagelsDepartment of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Ilse SmoldersCenter for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium.
Sebastiaan EngelborghsDepartment of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Vrije Universiteit Brussel · BEUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNocturnal cerebrospinal fluid (CSF) and blood melatonin levels are altered in Alzheimer's disease (AD). However, literature remains inconclusive on daytime blood melatonin levels. A positive correlation between melatonin levels and Mini-Mental State Examination (MMSE) scores in AD subjects has been evidenced following cross-sectional analyses. Whereas a correlation between serum and spinal CSF melatonin has been shown in healthy volunteers, an equal investigation in AD patients still has to be undertaken.

objective1) To evaluate whether serum melatonin levels correlate with spinal CSF melatonin levels in AD. 2) To compare daytime CSF and serum melatonin levels between patients with AD dementia, mild cognitive impairment due to AD, and healthy controls, and to evaluate whether melatonin can affect cognitive decline in AD.

methodsSubjects with AD and healthy controls included in two existing cohorts, of whom a CSF and serum sample was available at the neurobiobank and had at least 6 months of neuropsychological follow-up, were included in the present study. Melatonin concentrations were measured with liquid chromatography-mass spectrometry.

resultsDaytime serum melatonin levels correlated with spinal CSF melatonin levels in AD (r = 0.751, p < 0.001). No significant differences regarding daytime melatonin levels were found between patients and controls. No correlations were observed between daytime melatonin levels and MMSE score changes.

conclusionDaytime serum melatonin accurately reflects CSF melatonin levels in AD, raising the possibility to assess melatonin alterations by solely performing blood sampling if also confirmed for night-time values. However, daytime melatonin levels are not associated with changes of cognitive impairment.

Indexed as

Alzheimer DiseaseBiomarkersCognitive DysfunctionMelatoninAgedCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleNeuropsychological TestsBiomarkersMelatoninAlzheimer’s diseasecerebrospinal fluiddementiamelatonin

Identifiers

PMID34366353
PMCPMC8543270
OpenAlexW3189066899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.